A survey of people from 30 different countries around the world found that mental health was the biggest health problem respondents said was facing their country in 2025. Other health problems reported by respondents included cancer, stress, and obesity. The COVID-19 pandemic The COVID-19 pandemic impacted almost every country in the world and was the biggest global health crisis in recent history. It resulted in hundreds of millions of cases and millions of deaths, causing unprecedented disruption in health care systems. Lockdowns imposed in many countries to halt the spread of the virus also resulted in a rise of mental health issues as feelings of stress, isolation, and hopelessness arose. However, vaccines to combat the virus were developed at record speed, and many countries have now vaccinated large shares of their population. Nevertheless, in 2025, *** percent of respondents still stated that COVID-19 was the biggest health problem facing their country. Mental health issues One side effect of the COVID-19 pandemic has been a focus on mental health around the world. The two most common mental health issues worldwide are anxiety disorders and depression. In 2021, it was estimated that around *** percent of the global population had an anxiety disorder, while **** percent suffered from depression. Rates of depression are higher among females than males, with some *** percent of females suffering from depression, compared to *** percent of men. However, rates of suicide in most countries are higher among men than women. One positive outcome of the COVID-19 pandemic and the spotlight it shined on mental health may be a decrease in stigma surrounding mental health issues and seeking help for such issues. This would be a positive development, as many people around the world do not or cannot receive the necessary treatment they need for their mental health.

In 2021, there were over ** million deaths from all types of cardiovascular diseases all over the world. This statistic describes the number of deaths caused by selected chronic diseases worldwide in 2021. Chronic disease has widespread consequences on both individuals, impacting both quality and length of life, as well as on societies and governments worldwide. Chronic disease The burden of chronic diseases, which is made up of the resulting disabilities and deaths, is increasing all over the globe. In 2022, lung cancer caused over *** million deaths worldwide, accounting for the highest number of cancer deaths. Furthermore, it is estimated that by 2045, there will be *** million people living with diabetes all over the globe. Although chronic diseases are not curable, their risk factors are highly preventable, usually through individual lifestyle and behavioral modifications. Public policies have been put into place in many countries worldwide to promote healthier lifestyles, for example by limiting the consumption of tobacco and alcohol. Impact on societies Chronic diseases can result in a heavy economic burden due to related health care costs and through the loss of workforce. Countries of all income statuses are affected by chronic diseases, with the leading causes of death in high-income countries from chronic disease. Moreover, the rising impact of chronic disease in low-income countries leads to a double burden, as they are forced to deal with both infectious diseases and non-communicable diseases. Weak health systems and poor economies often pose limits to these countries’ abilities to cope as well.

This dataset provides comprehensive statistics on global health, focusing on various diseases, treatments, and outcomes. The data spans multiple countries and years, offering valuable insights for health research, epidemiology studies, and machine learning applications. The dataset includes information on the prevalence, incidence, and mortality rates of major diseases, as well as the effectiveness of treatments and healthcare infrastructure.

Dataset Use Cases:

This dataset can be used for:

• Healthcare Policy Analysis: Understanding which diseases are most prevalent and which countries require more investment in healthcare infrastructure.
• Epidemiological Studies: Studying the correlation between disease prevalence and socio-economic factors like income, education, and urbanization.
• Machine Learning Models: Training predictive models to forecast disease trends, mortality rates, and treatment effectiveness based on historical data.
• Global Health Research: Identifying regions that need targeted interventions or public health campaigns.

Heart conditions were the most common causes of death in Mexico in 2023. During that period, more than ******* people died in the North American country as a result from said conditions. Diabetes mellitus ranked second, with over ******* deaths registered that year. Obesity in MexicoObesity and being overweight can worsen many risk factors for developing heart conditions, prediabetes, type 2 diabetes, and gestational diabetes, which in the case of a COVID-19 infection can lead to a severe course of the disease. In 2020, Mexico was reported as having one of the largest overweight and/or obese population in Latin America, with ** percent of people in the country having a body mass index higher than 25. In 2022, obesity was announced as being one of the most common illnesses experienced in Mexico, with over ******* cases estimated. In a decade from now, it is predicted that about *** million children in Mexico will suffer from obesity. If estimations are correct, this North American country will belong to the world’s top 10 countries with the most obese children in 2030. Physical activity in MexicoIt is not only a matter of food intake. A 2023 survey found, for instance, that only **** percent of Mexican population practiced sports and physical activities in their free time, a figure that has decreased in comparison to 2013. Less than ** percent of the physically active Mexicans practice sports for fun. However, the vast majority were motivated by health reasons.

Tuberculosis is one of the most common causes of death globally.

By Saloni Dattani, Fiona Spooner, Hannah Ritchie and Max Roser

Data description:

In richer countries, the impact of tuberculosis has been reduced significantly over history, but in poorer parts of our world, it continues to be a major challenge even today: it causes an estimated 1.2 million deaths annually.

Tuberculosis is caused by the bacteria Mycobacterium tuberculosis.

The bacteria spreads through respiratory particles and tends to cause tuberculosis in people with risk factors such as undernourishment, HIV/AIDS, smoking, and existing chronic conditions.

The disease involves symptoms like coughing, fatigue and night sweats, and can damage the lungs, the brain, kidneys and other organs, which can be fatal.

But it is treatable with a combination of specific antibiotics. Without being diagnosed correctly, however, people do not receive the proper treatment. This leaves them vulnerable, and also increases the risk that antibiotic-resistant strains of the bacteria will develop, which are much more difficult and expensive to treat.

With greater effort to tackle its risk factors and improve testing and treatment for the disease, the world can relegate tuberculosis to history — not just in the richer parts of the world, but for everyone.

Data number 1: Tuberculosis is still common in many parts of the world In high-income countries, tuberculosis is largely a disease of the past. Since the beginning of the 20th century, its impact has been significantly reduced with the development of antibiotics and improvements in healthcare and living standards.

Data number 2: Tuberculosis kills over a million people annually, most of whom are adults Tuberculosis kills over a million people each year, as you can see in the chart. The chart shows that most of those who die from tuberculosis are adults.

Data number 3: Many people with tuberculosis are undiagnosed Although tuberculosis is typically a disease of the lungs, the bacteria can affect many organs in the body, and people who are infected don’t always have respiratory symptoms. Instead, they may experience weight loss, breathlessness, fever, or night sweats.

Data number 4: Antibiotic resistance is an important consideration during treatment People with tuberculosis require treatment with a specific combination of antibiotic medications that can kill the bacteria.

Data number 5: HIV increases the risk of developing tuberculosis An HIV infection is a major risk factor for developing tuberculosis.

Good luck

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fb75a86186a0014480c981c5182acc9ff%2Fgraph3.png?generation=1715898880551749&alt=media" alt="">this graph was created in Loocker studio,PowerBi,Tableau:

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ff695c5f66d6851cf80797b7057ade08b%2Fgraph1.jpg?generation=1715898858448928&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2F906461bf5b2ebc0f6bc6c806c9a1654e%2Fgraph2.jpg?generation=1715898864457964&alt=media" alt="">

Dementia patients show worsening cognitive function over time, beyond what might be expected from typical aging.

Dementia affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. This is commonly accompanied by changes in mood, emotional control, behavior, or motivation.

Deaths - Alzheimer's disease and other dementias - Sex: Both - Age: Age-standardized (Rate) Source Institute for Health Metrics and Evaluation, Global Burden of Disease (2019) – processed by Our World in Data Date range 1990–2019 Unit deaths per 100,000 people Links http://ghdx.healthdata.org/gbd-results-tool The data of this indicator is based on the following sources: Institute for Health Metrics and Evaluation, Global Burden of Disease (2019) Data published by Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2021.

Retrieved on September 22, 2021 Retrieved from http://ghdx.healthdata.org/gbd-results-tool How we process data at Our World in Data: All data and visualizations on Our World in Data rely on data sourced from one or several original data providers. Preparing this original data involves several processing steps. Depending on the data, this can include standardizing country names and world region definitions, converting units, calculating derived indicators such as per capita measures, as well as adding or adapting metadata such as the name or the description given to an indicator.

At the link below you can find a detailed description of the structure of our data pipeline, including links to all the code used to prepare data across Our World in Data.

Read about our data pipeline How to cite this data: In-line citation If you have limited space (e.g. in data visualizations), you can use this abbreviated in-line citation:

Institute for Health Metrics and Evaluation, Global Burden of Disease (2019) – processed by Our World in Data

Full citation

Institute for Health Metrics and Evaluation, Global Burden of Disease (2019) – processed by Our World in Data. “Deaths - Alzheimer's disease and other dementias - Sex: Both - Age: Age-standardized (Rate)” [dataset]. Institute for Health Metrics and Evaluation, Global Burden of Disease (2019) [original data].

It is estimated that around **** percent of the population in the United States has been diagnosed with an infectious disease. Infectious diseases are caused by bacteria, viruses and other organisms and can be spread from person to person, through insect or animal bites, or through contaminated food or water. Some of the most common infectious diseases include HIV/AIDS, influenza, malaria, tuberculosis and hepatitis.

HIV/AIDS

HIV/AIDS is one of the most well-known infectious diseases worldwide. There are currently almost ** million people worldwide living with HIV and it is responsible for just under a million deaths per year. HIV treatment has improved dramatically over the last few decades but access to treatment varies. The poorer regions of the world still suffer disproportionately from HIV with the majority of those infected living in Africa.

Tuberculosis

Like HIV/AIDS, tuberculosis also impacts the poorer regions of the world more than developed nations. Tuberculosis impacts the lungs of those infected and is currently the tenth leading cause of death worldwide. The countries with the highest incidence rates of tuberculosis include India, China, Indonesia, and the Philippines. In India alone tuberculosis was responsible for around ******* deaths in 2018.

Since 2008, HIV/AIDS remains the most fatal infectious disease in China. In 2021, almost ** out of one million people in China died from AIDS. Tuberculosis stood at the second place, while rabies ranked the fourth.

Who are the high risk groups?

The HIV/AIDS epidemic has become a growing concern for the major population in China. A majority of new infections were the result from sexual transmission. Although the prevalence rate has been relatively low, the trend of new diagnoses in people aged from 15 to 24 years has been alarming, with gay men disproportionately represented.

Children under the age of ** are the most vulnerable group to contract common infectious diseases like influenza and HFMD. The Chinese government has thus introduced healthcare initiatives dedicated to vaccinating children up to the age of ** under the Extended Program for Immunization (EPI). The efforts have been fruitful with significant improvement in the healthcare status of children under the age of **** in the country.

How is disease controlled in China?

The world’s most populous nation has made considerable efforts in tracking and preventing the spread of infectious diseases. Alongside geographical and demographic challenges, the mortality rate of infectious diseases has seen a slight increase over the recent years. Seasonal diseases, especially Influenza and mumps, are easily widespread and have pressed the demand for efficient disease prevention and control. In response, the Chinese government has ramped up the supply of influenza vaccines and HPV vaccines.

Cardiovascular diseases cover all diseases of the heart and blood vessels – including heart attacks and strokes, atherosclerosis, ischemic heart disease, hypertensive diseases, cardiomyopathy, and others.

These diseases tend to develop gradually with age, especially when people have risk factors like high blood pressure, smoking, alcohol use, poor diet, and air pollution.

Together, cardiovascular diseases are the most common cause of death globally.

In 2000, around 14 million people died from cardiovascular diseases globally, while in 2019, close to 18 million died.

The rising death toll is largely due to a growing and aging global population. Death rates from cardiovascular diseases have actually fallen in many countries – as our ability to prevent and treat them has improved.

Large declines in smoking; improvements in screening, diagnosis, and monitoring; and advances in medical treatments, public health initiatives, emergency care, and surgical procedures, have all helped to reduce the impact of cardiovascular diseases on people’s lives.

Yet large disparities remain globally. The impact of cardiovascular diseases can be reduced much further with greater understanding and public health efforts.

Original Data

Acknowlegement

Foto von Kenny Eliason auf Unsplash

ObjectiveWe analyzed the health needs of the adult population accessing public health facilities in the Iraqi Kurdistan, a region facing both demographic and epidemiological transitions while undergoing post-crisis recovery. We investigates the prevalence and distribution of communicable and non-communicable diseases using real-world data from a digital surveillance system.MethodsData collected across public health centers (PHC) were extracted from the KRG-DHIS2 digital health platform. All records from adult patients were coded using the WHO ICD-10. Diagnoses were grouped into: Communicable, maternal, neonatal and nutritional diseases (CMNNDs), Non-communicable diseases (NCDs), Injuries, Ill-defined diseases. Statistical analyses included descriptive statistics, age-related trends and sex-specific comparisons.ResultsA total of 1,040,695 health events were recorded (years 2016–2022) across 96 PHC: 899,173 were classified as either CMNNDs (41.1%) or NCDs (58.9%). Significant sex and age differences were observed across all major diagnostic categories. NCDs were more common in all age groups and increased significantly with age, while CMNNDs predominated among younger adults. Females accounted for 63.4% of all health events and exhibited higher rates of visits for endocrine, genitourinary, and hematologic conditions. Respiratory system diseases were the most common diagnoses across all ages, followed by genitourinary and digestive system diseases.ConclusionThis study provides critical evidence for understanding health service utilization and disease burden in Iraqi Kurdistan, using a real-time digital surveillance system. The findings confirm the presence of a double burden of disease in a population undergoing rapid transition and underscore the need for integrated, age-and sex-sensitive health interventions.

Depression is one of the most common health conditions globally. It's estimated that between two to six percent of people in the world have experienced depression in the past year.1

But what are the chances that people have depression at any time in their lives?

This question is difficult to answer because depression is not a constant condition – people tend to transition in and out of depressive episodes. The chances of ever having an episode of depression are therefore much higher than the figure of two to six percent.

Researchers estimate that around one in three women and one in five men in the United States have an episode of major depression by the time they are 65.2 Studies in other high-income countries suggest even higher figures. In the Netherlands and Australia, it's estimated that this affects 40% of women and 30% of men.3

In this post, I will explain why measuring the lifetime risk of depression can be challenging, and how researchers are able to address the challenges and estimate the risk of major depression over a person’s lifetime. One way to estimate the lifetime risk of depression is to ask elderly people whether they have ever had depression in their lives. This sounds straightforward, but it leads to several problems.

One is that it relies on self-reporting. Major depression is diagnosed based on the symptoms that people report to a professional. Since some are unwilling to share these symptoms, we would underestimate the risk of depression if we relied on this information alone.5

This is particularly important for older generations, who lived much of their lives at a time when recognition and acceptance of mental illness was lower. That relates to a second problem: people from different generations might be less willing to report symptoms.6

Another issue is that getting these estimates on a global level is difficult because this data is lacking across many countries. This is especially true for low-income countries.7 For example, the Global Burden of Disease study finds that only a quarter of countries and territories had direct data on the prevalence of major depression between 2005 and 2015.8

This means our findings mostly come from a small number of high-income countries where these studies have been done.

But even in countries where the data does exist, there is yet another major challenge. People often forget about previous episodes of depression – especially if they happened a long time ago. This is called ‘recall bias’, and it is one more problem that makes it hard to rely on people's self-report of symptoms of depression.

You can see this in the chart. This comes from a large study of people who were interviewed several times, years apart, about symptoms of mental and physical illness they had in their lives.9

Some people described having an episode of depression between one interview and the next. But some failed to recall episodes that they described in earlier interviews. This led to a more or less constant share who described lifetime depression at each interview.

As we might expect, older people were much more likely to forget previous symptoms. People older than 60 were around seven times more likely to forget past episodes than those under 50.

JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data was reported at 0.300 % in 2010. JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data is updated yearly, averaging 0.300 % from Dec 2010 (Median) to 2010, with 1 observations. JP: Prevalence of Severe Wasting: Weight for Height: Male: % of Children under 5 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Prevalence of severe wasting, male, is the proportion of boys under age 5 whose weight for height is more than three standard deviations below the median for the international reference population ages 0-59.; ; World Health Organization, Global Database on Child Growth and Malnutrition. Country-level data are unadjusted data from national surveys, and thus may not be comparable across countries.; Linear mixed-effect model estimates; Undernourished children have lower resistance to infection and are more likely to die from common childhood ailments such as diarrheal diseases and respiratory infections. Frequent illness saps the nutritional status of those who survive, locking them into a vicious cycle of recurring sickness and faltering growth (UNICEF, www.childinfo.org). Estimates of child malnutrition, based on prevalence of underweight and stunting, are from national survey data. The proportion of underweight children is the most common malnutrition indicator. Being even mildly underweight increases the risk of death and inhibits cognitive development in children. And it perpetuates the problem across generations, as malnourished women are more likely to have low-birth-weight babies. Stunting, or being below median height for age, is often used as a proxy for multifaceted deprivation and as an indicator of long-term changes in malnutrition.

Background: International travel during the Coronavirus disease 2019 (COVID-19) pandemic carries a certain magnitude of infection risk both to travelers and their destination, which may be difficult to assess in the early stage. The characteristics of common infectious diseases of tourists may provide some clues to identify the high-risk travelers and protect susceptible population.Methods: From among 48,444 travelers screened at Shanghai Port, we analyzed 577 travelers with 590 infectious diseases for age, sex, disease type, and World Health Organization (WHO) regions. We used the Joinpoint Regression Program to identify the average percent changes (APC) in the various trends among these individuals.Results: Hepatitis B, syphilis, and HIV were the most common infectious diseases in travelers entering China, and Hepatitis B, pulmonary tuberculosis, and syphilis in Chinese nationals traveling abroad (overall detection rates, 1.43 and 0.74%, respectively; P < 0.05). Africa (2.96%), the Americas (1.68%), and the Western Pacific (1.62%) exhibited the highest detection rates. This trend did not decrease since the COVID-19 pandemic (P > 0.05) and rather showed an upward trend with increasing age [APC 95% CI = 5.46 (3.41,7.56)%, P < 0.05]. However, there were no evident trends in monthly infection rates of travelers exiting and entering China from different WHO regions (all P > 0.05).Conclusion: Travelers always carry a transmission risk of common infectious diseases. It may be reasonable to adjust strategies for airport screening and quarantine according to the age and departure area of travelers to prevent and control new infectious diseases.

Medicare Chronic Condition Prevalence

Rates of Common Diseases in Washington State, 2007-2014

By Health [source]

About this dataset

This dataset contains information on the prevalence of chronic conditions among fee-for-service Medicare beneficiaries in Washington State and counties between 2007-2014. The data includes the percent of Medicare beneficiaries with conditions such as Alzheimer's Disease/Dementia, Arthritis, Asthma, Atrial Fibrillation, Autism Spectrum Disorders, Chronic Obstructive Pulmonary Disease (COPD), Cancer, Depression and Diabetes, among others. By gathering this data at both state and county level we are able to paint a comprehensive picture of the prevalence of these chronic conditions. This dataset provides an invaluable resource for researchers to gain insight into health disparities in different geographic areas and evaluate interventions aimed at improving health outcomes for these populations

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset contains information about the prevalence of chronic conditions among Medicare beneficiaries in Washington State and its counties from 2007 to 2014. It is useful for understanding the health needs of Medicare beneficiaries in this region, so that policy and service interventions can be tailored appropriately.

In order to use this data effectively, it is important to understand each of the columns provided. The ‘County’ column shows which county is being referred to for each record. The ‘Year’ column provides the year that data was taken for a particular county and indicates which time period it applies to. The ‘State and County FIPS Code’ identifies the region based on standard Federal Information Processing (FIPS) codes, while three numerical identifiers allow you to sort the data by county, year or both respectively – (To sort by county and year), (To sort by year and county) & (To sort by year and county). Finally, there are eleven columns indicating specific chronic conditions – Alzheimer's Disease/Dementia Prevalence (%), Arthritis Prevalence (%), Asthma Prevalence (%), Atrial Fibrillation Prevalence (%), Autism Spectrum Disorders Prevalence (% ), COPD Prevalence (%) ,Cancer Prevalence (%) ,Depression Prevalence % , Diabetes Preval

Research Ideas

• Using the chronic conditions prevalence data to create an interactive county-level map to identify health disparities across Washington state and counties.
• Analyzing the prevalence changes over time by chronic condition, county and/or demographic characteristics to inform health promotion efforts.
• Developing predictive models with the chronic conditions prevalence data that could help identify at risk individuals who are likely to develop specific health conditions in the future

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

License: Dataset copyright by authors - You are free to: - Share - copy and redistribute the material in any medium or format for any purpose, even commercially. - Adapt - remix, transform, and build upon the material for any purpose, even commercially. - You must: - Give appropriate credit - Provide a link to the license, and indicate if changes were made. - ShareAlike - You must distribute your contributions under the same license as the original. - Keep intact - all notices that refer to this license, including copyright notices.

Columns

File: Percents_of_Chronic_Conditions_among_Fee-for-Service_Medicare_Beneficiaries_Washington_State_and_Counties_2007-2014.csv | Column name | Description | |:---------------------------------------------------|:-----------------------------------------------------------------------------------------------------| | County | The name of the county in Washington State. (String) | | (To sort by county and year) | A unique identifier for each county and year combination. (Integer) | | (To sort by year and county) | A unique identifier for each year and county combination. (Integer) | | Year | The year of the data. (Integer) ...

ObjectivesTo quantify the burden and variation trends of cancers in children under 5 years at the global, regional, and national levels from 1990 to 2019.MethodsEpidemiological data for children under 5 years who were diagnosed with any one childhood cancer were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) from 1990 to 2019. The outcomes were the absolute numbers and rates of incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for different types of cancer.ResultsIn 2019, 8,774,979.1 incident cases (95% uncertainty interval [UI]: 6,243,599.2 to11,737,568.5) and 8,956,583.8 (6,446,323.9 to 12,364,520.8) prevalent cases of cancer in children under 5 years were identified worldwide; these cancers resulted in 44,451.6 (36,198.7 to 53,905.9) deaths and 3,918,014.8 (3,196,454.9 to 4,751,304.2) DALYs. From 1990 to 2019, although the numbers of incident and prevalent cases only decreased by −4.6% (−7.0 to −2.2) and −8.3% (−12.6 to −3.4), respectively, the numbers of deaths and DALYs clearly declined by −47.8% (−60.7 to −26.4) and −47.7% (−60.7 to −26.2), respectively. In 2019, the middle sociodemographic index (SDI) regions had the highest incidence and prevalence, whereas the low SDI regions had the most mortality and DALYs. Although all of the SDI regions displayed a steady drop in deaths and DALYs between 1990 and 2019, the low-middle and low SDI regions showed increasing trends of incidence and prevalence. Leukemia remained the most common cancer globally in 2019. From 1990 to 2019, the burdens of leukemia, liver cancer, and Hodgkin's lymphoma declined, whereas the incidence and prevalence of other cancers grew, particularly testicular cancer.ConclusionsThe global childhood cancer burden in young children has been steadily decreasing over the past three decades. However, the burdens and other characteristics have varied across different regions and types of cancers. This highlights the need to reorient current treatment strategies and establish effective prevention methods to reduce the global burden of childhood cancer.

The most common cause of death in Russia in 2023 was diseases of the circulatory system, with approximately *** deaths per 100,000 of the country's population. Furthermore, *** deaths per 100,000 population occurred due to neoplasms, which were the second leading cause of mortality in the country. The third-most common cause was diseases of the nervous system, accounting for nearly ** deaths per 100,000 residents. Are there more births or deaths in Russia per year? In recent years, the annual number of deaths was higher than the count of births in Russia. The natural decrease in the population, calculated as the difference between deaths and births, was around one million in 2021. The number of deaths per one thousand population, also known as the mortality rate, increased from **** in 2021 to **** in 2022. How long do Russians live on average? Russian residents born in 2022 were expected to live an average of ** years. The country had one of the largest gender gaps in life expectancy in the OECD, according to the World Bank's World Development Indicators in 2021. Women were expected to live for approximately ** years longer than men.

IntroductionThe demographic shift leads to a tremendous increase in age-related diseases, which are often chronic. Therefore, a focus of chronic disease management should be set on the maintenance or even improvement of the patients’ quality of life (QoL). One indicator to objectively measure QoL is the EQ-5D questionnaire, which was validated in a disease- and world region-specific manner. The aim of this study was to conduct a systematic literature review and meta-analysis on the QoL across the most frequent chronic diseases that utilized the EQ-5D and performed a disease-specific meta-analysis for treatment-dependent QoL improvement.Materials and methodsThe most common chronic disease in Germany were identified by their ICD-10 codes, followed by a systematic literature review of these ICD-10 codes and the EQ-5D index values. Finally, out of 10,016 independently -screened studies by two persons, 538 studies were included in the systematic review and 216 studies in the meta-analysis, respectively.ResultsWe found significant medium to large effect sizes of treatment effects, i.e., effect size >0.5, in musculoskeletal conditions with the exception of fractures, for chronic depression and for stroke. The effect size did not differ significantly from zero for breast and lung cancer and were significantly negative for fractures.ConclusionOur analysis showed a large variation between baseline and post-treatment scores on the EQ-5D health index, depending on the health condition. We found large gains in health-related quality of life mainly for interventions for musculoskeletal disease.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020150936, PROSPERO identifier CRD42020150936.

Global Animal Health Incident Reports (2005–2025)

Overview

This dataset contains two decades of global animal health incident reports, sourced from the World Organisation for Animal Health (WOAH, formerly OIE) via the WAHIS platform. It captures country-submitted disease reports for domestic and wild animal populations, standardized across time and geography for analysis.

The data spans from 2005 to 2025, covering more than 100 countries, and includes detailed reporting on: - Diseases like Avian Influenza, African Swine Fever, Foot and Mouth Disease, and Anthrax - Affected animal species (e.g., poultry, swine, cattle) - Report frequency over time and space - Outbreak context and resolution status

What's Inside

Why This Matters

This dataset provides a high-value lens into how global systems detect, report, and respond to animal health threats. These events impact not only food security and animal welfare, but also economic stability and zoonotic spillover risk.

It’s useful for: - Epidemiological modeling - Time series forecasting - Species vulnerability analysis - Regional disease burden tracking - Biosecurity planning and investment

Example Insights from the Notebook (Included)

• Monthly report volumes have more than tripled since 2010.
• Poultry is the most frequently affected species globally.
• Russia, Ukraine, and Germany are top reporters — possibly due to policy, proximity to outbreaks, and agri-intensity.
• HPAI and ASF have seen persistent growth across continents since the mid-2010s.
• Many reports lack species tagging, highlighting an opportunity for structured improvements.

📎 Companion Files

• animal_health_incidents.csv — Full dataset
• data_dictionary.csv — Column definitions
• README.md — Dataset background and methodology
• Global_Animal_Health_Incident_Reports.ipynb — Full exploratory notebook (optional)

Source

Data collected and cleaned from:
🌐 WOAH WAHIS Platform

Use responsibly under public reporting guidelines.

License

This dataset is released under CC0 Public Domain. Use, remix, and cite freely.

Ideas for Exploration

• Track disease emergence across time and space
• Compare reporting behavior between continents or income levels
• Build predictive models for disease outbreaks
• Integrate with climate, trade, or migration data
• Assess underreported diseases/species

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had been confirmed in almost every country in the world. The virus had infected over 687 million people worldwide, and the number of deaths had reached almost 6.87 million. The most severely affected countries include the U.S., India, and Brazil. COVID-19: background information COVID-19 is a novel coronavirus that had not previously been identified in humans. The first case was detected in the Hubei province of China at the end of December 2019. The virus is highly transmissible and coughing and sneezing are the most common forms of transmission, which is similar to the outbreak of the SARS coronavirus that began in 2002 and was thought to have spread via cough and sneeze droplets expelled into the air by infected persons. Naming the coronavirus disease Coronaviruses are a group of viruses that can be transmitted between animals and people, causing illnesses that may range from the common cold to more severe respiratory syndromes. In February 2020, the International Committee on Taxonomy of Viruses and the World Health Organization announced official names for both the virus and the disease it causes: SARS-CoV-2 and COVID-19, respectively. The name of the disease is derived from the words corona, virus, and disease, while the number 19 represents the year that it emerged.

Pediatric Smart Inhaler Spacers Market Outlook

As per our latest research, the global pediatric smart inhaler spacers market size reached USD 418.6 million in 2024, with a robust compound annual growth rate (CAGR) of 13.2% observed over the past year, driven primarily by technological advancements and increased awareness about pediatric respiratory health. The market is projected to grow significantly, reaching USD 1,167.8 million by 2033, according to our comprehensive analysis. This growth is underpinned by the rising prevalence of respiratory disorders among children and the increasing adoption of smart inhaler technologies, which are transforming pediatric respiratory care globally.

The growth of the pediatric smart inhaler spacers market is being propelled by an alarming rise in pediatric respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization, asthma remains one of the most common chronic diseases among children, affecting millions worldwide. The increased incidence of these conditions has necessitated the development and adoption of advanced inhalation therapies. Smart inhaler spacers, equipped with digital tracking and monitoring features, are now seen as essential tools for improving medication adherence, reducing hospitalizations, and enhancing disease management outcomes. These devices provide real-time feedback and reminders, ensuring that young patients receive the correct dosage at the right time, thereby minimizing the risk of exacerbations and emergency room visits.

Another significant growth factor for the pediatric smart inhaler spacers market is the integration of digital health technologies such as Bluetooth-enabled and sensor-based devices. These innovations are revolutionizing the way caregivers and healthcare providers monitor and manage pediatric respiratory conditions. The ability to track inhaler usage data, monitor adherence remotely, and share real-time information with physicians is greatly enhancing personalized care for children. Additionally, the proliferation of smartphones and mobile health applications has facilitated the widespread adoption of these smart devices, making it easier for parents and caregivers to manage their child’s respiratory health efficiently. This digital transformation is expected to continue driving market expansion, as stakeholders increasingly recognize the value of connected health solutions in pediatric care.

Government initiatives and supportive healthcare policies play a crucial role in fueling the growth of the pediatric smart inhaler spacers market. Several countries have implemented programs aimed at improving pediatric respiratory care, including subsidies for advanced inhalation devices and awareness campaigns about the importance of medication adherence. Collaborations between device manufacturers, healthcare providers, and insurance companies are also fostering greater accessibility and affordability of smart inhaler spacers. Furthermore, ongoing research and development activities are leading to the introduction of more user-friendly, cost-effective, and technologically advanced products, catering to the unique needs of pediatric patients. These collective efforts are expected to sustain the upward trajectory of the market over the forecast period.

From a regional perspective, North America currently dominates the pediatric smart inhaler spacers market, accounting for the largest share in 2024. This leadership is attributed to the region’s high healthcare expenditure, advanced technological infrastructure, and strong presence of key market players. Europe follows closely, driven by robust healthcare systems and increasing adoption of digital health solutions. The Asia Pacific region is witnessing the fastest growth, fueled by rising healthcare awareness, improving access to medical devices, and a large pediatric population base. Latin America and the Middle East & Africa are also showing promising growth potential, supported by ongoing healthcare reforms and increasing investments in pediatric respiratory care. These regional trends underscore the global nature of market expansion and the diverse opportunities available across different geographies.

Product Type Analysis

The product type segment of the pediatric smart inhaler spacers market is primarily divided into valved holding chambers and non-valved spacers.